Alembic Pharmaceuticals has received a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025 (Q3 2026). The certificate, received from MUFG Intime India Private Limited, confirms the dematerialization of securities. This announcement confirms compliance with regulatory requirements.
Compliance Confirmation
Alembic Pharmaceuticals has announced the receipt of a compliance certificate related to the handling of securities during the third fiscal quarter of 2026. The certificate specifically addresses the regulations concerning depositories and participants.
Details of the Certification
The certificate, as stated in the company’s communication, is issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This covers the period for the quarter ended December 31, 2025 (Q3 2026). It confirms that all securities received for dematerialization during this period have been appropriately processed.
Issuing Authority
The certificate was provided by MUFG Intime India Private Limited, which serves as the Registrar and Share Transfer Agent for Alembic Pharmaceuticals. This firm has verified the dematerialization process in compliance with regulatory standards for the reporting period.
Source: BSE
